This Article Full Text Full Text (PDF) Supplemental material Other Versions of this Article: CVI.00106-07v1 15/2/297    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Sánchez Negrette, O. Articles by Basombrío, M. A. PubMed PubMed Citation Articles by Sánchez Negrette, O. Articles by Basombrío, M. A.

Serological Evaluation of Specific-Antibody Levels in Patients Treated for Chronic Chagas' Disease^,

Instituto de Patología Experimental, Facultad de Ciencias de la Salud, Universidad Nacional de Salta, calle Buenos Aires 177, 4400 Salta, Argentina

Received 2 January 2007/ Returned for modification 27 April 2007/ Accepted 19 November 2007

Serological tests are the main laboratory procedures used for diagnosis during the indeterminate and chronic stages of Chagas' disease. A serological regression to negativity is the main criterion used to define parasitological cure in treated patients. The aim of this work was to monitor the individual specificities of antibody levels for 3 years posttreatment in 18 adult patients. Conventional serological techniques (hemagglutination assays and enzyme-linked immunosorbent assay [ELISA]) were modified by using recombinant antigens to detect early markers of treatment effectiveness. For this purpose, serum samples were taken before and during treatment and every 6 months after treatment for at least 3 years. When hemagglutination assays were used, a decrease in antibody levels was observed in only one patient. When ELISA with serum dilutions was used, antibody clearance became much more apparent: in 77.7% (14/18) of the patients, antibody titers became negative with time. This was observed at serum dilutions of 1/320 and occurred between the 6th and the 30th months posttreatment. The immune response and the interval for a serological regression to negativity were different for each patient. For some of the recombinant antigens, only 50% (9/18) of the patients reached the serological regression to negativity. Recombinant antigen 13 might be a good marker of treatment effectiveness, since 66.6% (six of nine) of the patients presented with an early regression to negativity for specific antibodies to this antigen (P = 0.002).

Published ahead of print on 5 December 2007.

Supplemental material for this article may be found at http://cvi.asm.org/.